77 research outputs found
The endocannabinoid system in mental disorders: Evidence from human brain studies
Mental disorders have a high prevalence compared with many other health conditions and are the leading cause of disability worldwide. Several studies performed in the last years support the involvement of the endocannabinoid system in the etiopathogenesis of different mental disorders. The present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. We will focus on the findings from human brain studies regarding alterations in endocannabinoid levels, cannabinoid receptors and endocannabinoid metabolizing enzymes in patients suffering mental disorders.
Studies carried out in humans have consistently demonstrated that the endocannabinoid system is fundamental for emotional homeostasis and cognitive function. Thus, deregulation of the different elements that are part of the endocannabinoid system may contribute to the pathophysiology of several mental disorders. However, the results reported are controversial. In this sense, different alterations in gene and/or protein expression of CB1 receptors have been shown depending on the technical approach used or the brain region studied. Despite the current discrepancies regarding cannabinoid receptors changes in depression and schizophrenia, present findings point to the endocannabinoid system as a pivotal neuromodulatory pathway relevant in the pathophysiology of mental disorders.This study was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-67457-R, MINECO/FEDER), the Plan Estatal de I+D+i 2013-2016, the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación, Spanish Ministry of Economy, FEDER (PI13/01529) and the Basque Government (IT616/13). I I-L is a recipient of a Predoctoral Fellowship from the Basque Government. E F-Z is a recipient of a Predoctoral Fellowship from the University of Cantabria. CM is a recipient of a Postdoctoral Marie Skłodowska-Curie Individual Fellowship (H2020-MSCA-IF-2016, ID 747487)
The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study
Abstract
Background: Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD).
Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD.
Aims: This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort
Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance
Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to
treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for
treatment outcomes. This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months.
Results: A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment
period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36.7 years (11.0); 47.5% were inpatients
and 52.5% outpatients; The most prevalent SUDs were with alcohol 54.2%, stimulants 43.6%, cannabis 33.1%, Abstract
Background: Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD).
Although the short-term effects of some specific interventions have been investigated in randomized clinical trials,
little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD.
Aims: This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort
Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance
Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to
treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for
treatment outcomes.
This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD
patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period
of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of
cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months.
Results: A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment
period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36.7 years (11.0); 47.5% were inpatients
and 52.5% outpatients; The most prevalent SUDs were with alcohol 54.2%, stimulants 43.6%, cannabis 33.1%, and opioids 14.5%. Patients reported previous treatments for SUD in 71.1% and for ADHD in 56.9%. Other comorbid mental disorders were present in 61.4% of the sample: major depression 31.5%, post-traumatic stress disorder 12.1%, borderline personality disorder 10.2%. Conclusions: The first baseline results of this international cohort study speak to its feasibility. Data show that many SUD patients with comorbid ADHD had never received treatment for their ADHD prior to enrolment in the study.
Future reports on this study will identify the course and potential predictors for successful pharmaceutical and psychological
treatment outcomes
International consensus statement for the screening, diagnosis, and treatment of adolescents with concurrent Attention-Deficit/Hyperactivity Disorder and substance use disorder
Education and Child Studie
Caractérisation clinique et génétique des symptômes suicidaires et des troubles psychiatriques associés aux addictions
Caractérisation clinique et génétique des symptômes suicidaires et des troubles psychiatriques associés aux addictions
Intérêt de l'étude spécifique de l'addiction chez les sujets âgés de plus de 65 ans (place de la géronto-addictologie)
BORDEAUX2-BU Santé (330632101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Variability and vulnerability to comorbid conditions in addictive disorders
Addictive disorders are a major burden worldwide, including high mortality rates. Part of this burden can be attributed to comorbid psychiatric disorders, especially suicidal behavior. Our project aims at characterizing the genetic and clinical vulnerability associated with the comorbidity between addictive and psychiatric disorders, focusing on suicidal risk
Dysfunctional Parental Styles Perceived during Childhood in Outpatients with Substance Use Disorders
International audiencePeople who suffer from substance use disorders (SUDs) frequently report to have undergone childhood adversity that is often associated with father or mother dysfunction, or both. Yet that issue has been barely addressed in opiate dependent patients. Therefore we sought to evaluate parent-specific dysfunctional styles perceived during childhood in a clinical sample from an outpatient addiction treatment program using the Measure Of Parental Styles (MOPS) questionnaire. DSM-IV diagnoses of substance use disorders and history of suicide attempts, family structure and changes of caregiver during childhood were obtained from 159 consecutive outpatients, along with their perception of parental bonding with the MOPS, in which mother and father scores are separate. Mother neglect dimension was significantly correlated with an earlier age at onset of several substances' use, the number of prior hospitalizations and of lifetime suicide attempts. Most of these associations remained significant in multivariate models. This was the first assessment of a representative sample of outpatients with SUDs by the MOPS questionnaire. Given its excellent acceptance and its association with several key correlates of SUDs, it should be used to design specific interventions targeted at attachment and familial management as well as in research models on gene \texttimes environment interactions
Feasibility and Acceptability of the \u27HABIT\u27 Group Programme for Comorbid Bipolar and Alcohol and Substance use Disorders
Feasibility and Acceptability of the 'HABIT' Group Programme for Comorbid Bipolar and Alcohol and Substance Use Disorders
OBJECTIVES: We investigated the feasibility and acceptability of an integrated group therapy (called HABIT) for comorbid bipolar disorder (BD) and alcohol and substance use disorders (ASUD) (BD-ASUD), a disabling clinical presentation for which no specific treatment has been validated. The 14-session HABIT programme employs psychoeducation-oriented cognitive-behaviour therapy (CBT) followed by mindfulness-based relapse prevention (MBRP) therapy. METHOD: Potential group participants were recruited from adult clients with a DSM-IV diagnosis of BD and an ASUD who were referred by their treating clinician. Observer-rated changes in mood symptoms and ASUD, attendance rates and subjective feedback are reported. RESULTS: Eight of 12 clients referred to the programme initially agreed to join the group, six attended the first group session and five clients completed the programme. Group mean scores for mood symptoms improved over time, with slightly greater reductions in depression during the first module. About 50% of individuals showed clinically significant improvement (≥q30% reduction) in alcohol and substance use. Attendance rates showed some variability between individuals and across sessions, but the average attendance rate of the group was marginally higher for the first module (86%) as compared with the second module (77%). Most clients reported high levels of general satisfaction with a group specifically targeted at individuals with BD-ASUD. CONCLUSION: This small pilot study suggests our intensive group therapy is acceptable and feasible. If findings are replicated, we may have identified a therapy that, for the first time, leads to improvement in both mood and substance use outcomes in clients with difficult-to-treat comorbid BD-ASUD. Copyright \textcopyright 2016 John Wiley & Sons, Ltd. Key Practitioner Message Comorbidity between bipolar and alcohol and substance use disorders (BD-ASUD) is frequent and highly disabling; Therapeutic research on approaches that can simultaneously help BD and ASUD is lacking; Previous research highlights the need for integrated treatment of both conditions but showed improvements limited to either element of the comorbid disorder; This pilot study supports the feasibility and acceptability of an intensive, 14-session group therapy programme that integrates CBT and mindfulness approaches
- …